Edison Investment Research - Threshold Pharmaceuticals Inc. (NZW2) QuickView: Pivotal STS Phase III continues as planned

Report

Edison Investment Research

QuickView: Pivotal STS Phase III continues as planned

The conclusion of the interim efficacy and safety analysis of Thresholdâ€™s ongoing Phase III soft tissue sarcoma (STS) trial is for the study to continue as planned, in line with both our and managementâ€™s expectations. Based on the current event rate, the number of events (n=434 deaths) required for the primary efficacy analysis are expected to be reached in H215. STS could be the first approved indication for TH-302.

24/09/2014 2 EN

Underlying

Threshold Pharmaceuticals Inc.

See profile

US8858072064 United States

Provider

Edison Investment Research

Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.

See profile

Other Reports on these Companies

GlobalData Plc

Threshold Pharmaceuticals Inc (THLD) - Medical Equipment - Deals and Alliances Profile.

Summary Threshold Pharmaceuticals Inc (Threshold) is a biotechnology company that discovers and develops tumour-targeted therapies. The companyâ€™s clinical pipeline includes TH-CR-406, MAESTRO, TH-CR-413, TH-CR-408, TH-IST-4003, TH-IST-4004, TH-CR-410, TH-CR-407 and TH-IST-4001. Its products include evofosfamide, TH-4000 and [18F]-HX4. Thresholdâ€™s evofosfamide and TH-4000 are under evaluation for the treatment of a variety of tumor types. Threshold offers evofosfamide is a investigational hypoxia-activated pro-drug. The companyâ€™s [18F]-HX4 is an in-licensed positron emission tomography i...

EUR 220.94

July 20, 2017 July 20, 2017 30 EN

Edison Investment Research

Update: Big in Japan?

Following analysis of the Phase III data of evofosfamide (TH-302) in unresectable or metastatic pancreatic cancer patients, which failed on an intent-to-treat basis (p=0.0588), Threshold Pharmaceuticals has announced that the drug seemed to demonstrate impressive efficacy among the patients in Japan. Overall survival in the Japanese subset was 13.6 months vs 9.1 months in the control arm (p=0.0106). The company is currently seeking a partner in Japan and reaching out to the Pharmaceutical and Medical Device Agency (PMDA) to understand the potential path forward.

April 28, 2016 April 28, 2016 7 EN

Edison Investment Research

Flash note: Disappointing Phase III evofosfamide data

Evofosfamide has not met the primary endpoint of improving overall survival in two Phase III trials in soft tissue sarcoma (STS) and pancreatic cancer. Although some benefit was seen in pancreatic cancer, partner Merck KGaA will not file either indication with regulators and Threshold expects Merck to terminate the agreement. If this occurs, Threshold will consider all options for future evofosfamide development, which could include in combination with checkpoint inhibitors. We have placed our valuation and forecasts under review pending further updates. Threshold is now trading broadly in lin...

December 9, 2015 December 9, 2015 2 EN

Record - AUME momentum and a sharper focus

Record’s Q424 trading update demonstrated continued growth in assets under management equivalent (AUME), which will support management fee growth into FY25. In FY24, AUME grew 17% to US$102.2bn, setting a new milestone in business scale. Net inflows for FY24 were US$6.8bn (FY23: US$9.1bn) or 8% of opening AUME. Performance fees of US$5.8m matched the record FY23 figure, and we expect this to offset the negative product mix in FY24. We have reduced our FY24e EPS by 1%, which is affected by £2.4bn in IT restructuring and impairment charges announced in March 2024. New CEO Dr Jan Witte is putting...

14h / 53m 14h / 53m 1 EN

Sean Conroy

Sean Conroy

Actinogen Medical - Funding in place through key catalysts

Actinogen announced a capital increase of up to A$8.9m on 3 May, consisting of a A$5.0m (gross) placement along with a shareholder rights offering (‘entitlement offer’) designed to raise up to A$3.9m (gross) from existing shareholders. The closing date of the rights offer is 29 May and, given that Actinogen shares are currently trading at c A$0.028, we assume full exercise of the rights offering in Q424 (Q2 CY24). The company expects that the proceeds (assuming full exercise of the rights offering) will extend its operating runway beyond the interim results release of the first 100 patients of...

May 15, 2024 May 15, 2024 1 EN

Pedro Fonseca

Pedro Fonseca

Henderson Opportunities Trust - A differentiated exposure to smaller companies

With a focus on long-term growth, Henderson Opportunities Trust (HOT) seeks investment opportunities across the breadth of the UK market. This includes a strong bias towards smaller and earlier-stage companies with significant potential to become tomorrow’s leading British businesses. There are tentative signs that the significant three-year underperformance of these smaller companies, and of HOT, may be coming to an end. If so, the trust is well placed to benefit and its differentiated, truly all-market approach is one that many investors would struggle to replicate. Moreover, HOT’s size and ...

May 15, 2024 May 15, 2024 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

QuickView: Pivotal STS Phase III continues as planned

Threshold Pharmaceuticals Inc (THLD) - Medical Equipment - Deals and Alliances Profile.

Update: Big in Japan?

Flash note: Disappointing Phase III evofosfamide data

Record - AUME momentum and a sharper focus

Actinogen Medical - Funding in place through key catalysts

Henderson Opportunities Trust - A differentiated exposure to smaller companies

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe